Anti-Human CD150 FITC 25 tests
- Known as:
- Antibody toHuman CD150 fluorecein 25 tests
- Catalog number:
- 11-1509-41
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Human CD150 FITC 25 tests
Related genes to: Anti-Human CD150 FITC 25 tests
- Gene:
- SLAMF1 NIH gene
- Name:
- signaling lymphocytic activation molecule family member 1
- Previous symbol:
- SLAM
- Synonyms:
- CD150
- Chromosome:
- 1q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-08-06
- Date modifiied:
- 2014-11-18
Related products to: Anti-Human CD150 FITC 25 tests
Related articles to: Anti-Human CD150 FITC 25 tests
- B7-H4, a member of the B7 family, is broadly expressed on various cancer cells and has been implicated in negative immune regulation, particularly in suppressing anti-tumor immunity. However, its receptor and the mechanisms underlying its immunosuppression remain poorly understood. Here, we identify Galectin-9 (Gal-9) as a binding partner of B7-H4 and investigate its role in modulating T cell responses. We show that glycosylation within the IgC domain of B7-H4 is required for Gal-9 binding, while the N-terminal carbohydrate recognition domain (N-CRD) of Gal-9-specifically residue R65-is essential for its binding with B7-H4. In addition, several other B7 family members (B7.1, B7.2, B7-H2, and B7-DC) and immune cell surface receptors (CD28, 2B4, CD226, and SLAMF1) also bind to Gal-9 at levels comparable to those observed with B7-H4 or TIM-3. In vitro functional assays revealed that B7-H4 inhibits Gal-9-induced activation of CD28 downstream signaling and reduces Gal-9-mediated T cell death. In vivo, Gal-9 deficiency in mice resulted in an increased proportion of splenic CD4+ T cells, whereas B7-H4 deficiency produced no detectable phenotype. Moreover, B7-H4 and Gal-9 double-knockout mice showed no additive phenotype compared with Gal-9 single-knockout mice, and tumor growth following tumor cell challenge was unaffected in all three knockout models. Collectively, these findings indicate that B7-H4, Gal-9, other B7 family members, and T cell surface immune receptors form a complex regulatory network that modulates T cell activity and anti-tumor responses, with no single component exerting a dominant effect. This study provides a detailed molecular characterization of the B7-H4-Gal-9 interaction and uncovers additional Gal-9 binding partners, offering insights into the finely tuned immune regulation mediated by the B7 family. - Source: PubMed
Publication date: 2026/09/18
Wang Ravear ZhiqiangYang FangSui Jianhua - encodes CD150, an immunoregulatory receptor involved in lymphocyte activation, T-B-cell interactions, and humoral immune responses. The promoter polymorphism rs2295613(G>A) was previously associated with systemic lupus erythematosus (SLE) susceptibility in a Chinese case-control cohort. Here, we investigated the regulatory activity of rs2295613 in the transformed B-cell lines Raji and MP1 and in primary human CD19 B cells. The rs2295613(A)-containing reporter showed higher promoter activity than the rs2295613(G)-containing reporter in all three cellular systems. Bioinformatic analysis predicted that the G to A substitution strengthens a pre-existing MYC-compatible motif. Substitutions disrupting the motif-containing region attenuated the rs2295613(A)-associated increase in reporter activity and reduced enrichment of the promoter fragment in anti-c-MYC DNA pull-down assays. Partial siRNA-mediated reduction in MYC mRNA also decreased the activity of the rs2295613(A)-containing reporter in Raji cells. Together, these findings identify rs2295613 as a functional promoter variant in B-cell reporter systems and support a contribution of c-MYC-associated regulation to the enhanced activity of the rs2295613(A)-containing promoter. - Source: PubMed
Publication date: 2026/08/28
Uvarova Aksinya NPutlyaeva Lidia VKorneev Kirill VStasevich Ekaterina MPrikhodko Elvina AMurashko Matvey MDemin Denis EZheremyan Elina ASchwartz Anton MKuprash Dmitry V - An estimated 2.1 billion people are infected with () and at risk of developing active tuberculosis (TB). Because exists in replicating and dormant states, effective vaccines should target antigens from both stages. Here, we evaluated the immunogenicity and vaccine potential of dormancy antigen Rv2626c. Cellular and humoral immune responses were studied in individuals with latent TB infection (LTBI), active TB, and healthy donors (HD) using flow cytometry and ELISA. Overlapping peptides spanning Rv2626c sequence and structural mapping were employed to characterize Rv2626c immunogenic regions. Additionally, the protective efficacy of a Modified Vaccinia Ankara (MVA) vector expressing Rv2626c was evaluated in a murine challenge model. Rv2626c induced cellular immunity selectively in LTBI, characterized by increased frequencies of CD4IFN-γ, SLAMF1, and poly-functional T lymphocytes. Immunodominant peptide regions were identified across the protein sequence. Moreover, mice immunized with MVA-Rv2626c showed a significant reduction in splenic bacterial burden following a challenge with H37Rv. Altogether, our findings indicate that the latency-associated antigen Rv2626c elicits immune responses in LTBI subjects and limits bacterial dissemination in our mice model of infection. Therefore, Rv2626c arises as a promising candidate to be combined with active phase antigens in multistage vaccines against infection. - Source: PubMed
Publication date: 2026/09/01
Zuazo RocíoBazán Bouyrie Ana JuliaVitti Agustín DanielMorelli María PaulaMartin CandelaSantos JavierMusella RosaPalmero Domingo JuanCalamante GabrielaDel Médico Zajac María PaulaAmiano Nicolás OscarGarcía Verónica Edith - CD150-positive (CD150) lymphocytes are the primary targets of measles virus (MV) infection during the acute phase. The depletion of infected CD150 memory cells leads to a profound suppression of immune memory, resulting in increased susceptibility to secondary infections and severe complications in infected individuals. While lipids are known to be critical for viral life cycles, the specific lipid metabolic conditions facilitating MV replication in immune cells remain poorly understood. - Source: PubMed
Publication date: 2026/08/19
Grijalva Yépez Maria FernandaCordes Yann LoïcFekete AgnesSchumacher FabianKleuser BurkhardAvota Elita - In order to investigate the therapeutic mechanism of Jianpiyiqi Granule in juvenile myasthenia gravis (JMG) and find the immune-associated cytokines or signaling pathways targeted by this intervention. - Source: PubMed
Geng YuanyuanLiu PengJin MinQi GuoyanLin XiaotingZhang Yousheng